Table 1.

Demographic characteristics of patient sample (adults with moderate–severe RA) with breakdown by currently used autoinjector (n=200)

		Currently used autoinjector
		Molly® for etanercept (Benepali), n=54	MyClic® for etanercept (Enbrel), n=70	Humira® pen for adalimumab (Humira), n=76
Sex
Female	64%	61%	64%	66%
Male	36%	39%	36%	34%
Age
Average	52 years	55 years	51 years	50 years
≤30 years	2%	0	1%	4%
31–40 years	12%	6%	17%	11%
41–50 years	29%	24%	29%	32%
51–60 years	36%	41%	33%	34%
61–69 years	23%	30%	20%	20%
Highest level of education
Primary school	2%	2%	0	3%
Secondary school	29%	31%	27%	28%
High school	36%	39%	33%	36%
University	35%	28%	40%	34%
Duration of use
Average	27 months	7 months	32 monthsa	37 monthsa
≤12 months	47%	89%b,c	34%	29%
13–36 months	34%	11%	47%a	38%a
>36 months	19%	0	19%a	33%a
Country
France	18%	11%	21%	20%
Germany	23%	28%	21%	20%
Italy	23%	28%	21%	20%
Spain	14%	6%	11%	21%a,b
UK	24%	28%	24%	20%

Notes:

^aSignificantly higher than Benepali (P<0.01);

^bsignificantly higher than Enbrel (P<0.01);

^csignificantly higher than Humira (P<0.01). Two-tailed significance tests.

Abbreviation: RA, rheumatoid arthritis.